The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study
- PMID: 22223235
- PMCID: PMC3289043
- DOI: 10.1161/STROKEAHA.111.625574
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study
Abstract
Background and purpose: Argatroban is a direct thrombin inhibitor that safely augments recanalization achieved by tissue-type plasminogen activator (tPA) in animal stroke models. The Argatroban tPA Stroke Study was an open-label, pilot safety study of tPA plus Argatroban in patients with ischemic stroke due to proximal intracranial occlusion.
Methods: During standard-dose intravenous tPA, a 100-μg/kg bolus of Argatroban and infusion for 48 hours was adjusted to a target partial thromboplastin time of 1.75× baseline. The primary outcome was incidence of significant intracerebral hemorrhage defined as either symptomatic intracerebral hemorrhage or Parenchymal Hematoma Type 2. Recanalization was measured at 2 and 24 hours by transcranial Doppler or CT angiography.
Results: Sixty-five patients were enrolled (45% men, mean age 63±14 years, median National Institutes of Health Stroke Scale=13). The median (interquartile range) time tPA to Argatroban bolus was 51 (38-60) minutes. Target anticoagulation was reached at a median (interquartile range) of 3 (2-7) hours. Significant intracerebral hemorrhage occurred in 4 patients (6.2%; 95% CI, 1.7-15.0). Of these, 3 were symptomatic (4.6%; 95% CI, 0.9-12.9). Seven patients (10%) died in the first 7 days. Within the 2-hour monitoring period, transcranial Doppler recanalization (n=47) occurred in 29 (61%) patients: complete in 19 (40%) and partial in another 10 (21%).
Conclusions: The combination of Argatroban and intravenous tPA is potentially safe in patients with moderate neurological deficits due to proximal intracranial arterial occlusions and may produce more complete recanalization than tPA alone. Continued evaluation of this treatment combination is warranted.
Clinical trial registration: URL: www.clinicaltrials.gov. Unique identifier: NCT00268762.
Conflict of interest statement
Conflict of Interest
Figures
Comment in
-
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.Stroke. 2012 Mar;43(3):623-4. doi: 10.1161/STROKEAHA.111.640557. Epub 2012 Jan 5. Stroke. 2012. PMID: 22223236 No abstract available.
References
-
- Walenga JM. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb. 2002;32 (Suppl 3):9–14. - PubMed
-
- Tanaka KA, Szlam F, Katori N, Sato N, Vega JD, Levy JH. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg. 2004;99:1283–1289. - PubMed
-
- Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tpa) in acute myocardial infarction: Myocardial infarction with novastan and tpa (MINT) study. J Am Coll Cardiol. 1999;33:1879–1885. - PubMed
-
- Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of argatroban. J Thromb Thrombolysis. 2001;12:141–149. - PubMed
-
- Wykrzykowska JJ, Kathiresan S, Jang IK. Clinician update: Direct thrombin inhibitors in acute coronary syndromes. J Thromb Thrombolysis. 2003;15:47–57. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- T32 NS007412/NS/NINDS NIH HHS/United States
- T32NS07412/NS/NINDS NIH HHS/United States
- P50 NS044227/NS/NINDS NIH HHS/United States
- 1P50NS044227/NS/NINDS NIH HHS/United States
- K23 NS002229/NS/NINDS NIH HHS/United States
- KL2 TR000370/TR/NCATS NIH HHS/United States
- 1K23NS02229-01/NS/NINDS NIH HHS/United States
- UL1 TR000371/TR/NCATS NIH HHS/United States
- KL2 RR024149/RR/NCRR NIH HHS/United States
- TL1 RR024147/RR/NCRR NIH HHS/United States
- UL1 RR024148/RR/NCRR NIH HHS/United States
- P50NS044227/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
